Journal of Urban Health

, Volume 84, Issue 1, pp 116–125

Increasing Syringe Access and HIV Prevention in California: Findings from a Survey of Local Health Jurisdiction Key Personnel

  • Thomas J. Stopka
  • Richard S. Garfein
  • Alessandra Ross
  • Steven R. Truax
Article

Abstract

This article presents results from the first survey of California local health jurisdictions (LHJs) subsequent to passage of legislation that allows for over-the-counter pharmacy sales of syringes. In 2004 Governor Arnold Schwarzenegger signed Senate Bill 1159 (SB1159) into law to “prevent the spread of HIV, hepatitis and other blood-borne disease among drug users, their sexual partners and their children.” This legislation permits counties and cities to authorize a local disease prevention demonstration project (DPDP). Once authorized, a DPDP permits individuals to legally purchase and possess up to ten syringes from registered pharmacies without a doctor’s prescription. From June to August 2005, we surveyed health departments in all 61 LHJs to assess implementation status of SB1159. Fifty-seven (93%) LHJs responded. Nine (16%) had approved a DPDP by August 2005, 17 (30%) were in the process of obtaining authorization, and 18 (32%) anticipated that SB1159 would never be authorized in their LHJ. Among LHJs that do not plan to approve a DPDP (n = 18), the reasons included: strong community opposition (41%), competing priorities (35%), law enforcement opposition (29%), and little or no interest among pharmacies (29%). In LHJs that have authorized a DPDP, 31.4% of pharmacies registered to legally sell nonprescription syringes. Preliminary results indicate that local coalitions, comprised of public health, waste management and pharmacy officials, have been instrumental in facilitating DPDP authorization. Further research is needed to identify facilitators and barriers to adopting SB1159, to identify areas for improving technical assistance to implementers, and to assess the public health impact of the legislation.

Keywords

Health policy HIV/AIDS Injection drug use Pharmacies Sterile syringe access. 

References

  1. 1.
    California Department of Health Services Office of AIDS. Cumulative AIDS case data through January 31, 2006. Accessed on March 7, 2006. Available at: http://www.dhs.ca.gov/aids/Statistics/pdf/Stats2006/Jan06AIDSmerged.pdf.
  2. 2.
    Facer MS, Ritieni A, Marino J, et al. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California. Sacramento: California Department of Health Services; 2001.Google Scholar
  3. 3.
    California Department of Health Services. The Hepatitis C Strategic Plan. A Collaborative Approach to the Emerging Epidemic in California. Sacramento: Disease Investigations and Surveillance Branch, Hepatitis C Prevention and Control Unit; 2001.Google Scholar
  4. 4.
    Williams IT. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S–9S.PubMedCrossRefGoogle Scholar
  5. 5.
    Burris S, Vernick J, Ditzler A, Strathdee S. The legality of selling or giving syringes to injection drug users. J Am Pharm Assoc. 2002;42(Suppl 2):S13–S18.Google Scholar
  6. 6.
    Singer M, Baer H, Scott G, Horowitz S, Weinstein B. Pharmacy access to syringes among injection drug users: follow-up findings from Hartford, Connecticut. Public Health Rep. 1998;113(Suppl 1):81–89.PubMedGoogle Scholar
  7. 7.
    Compton WM, Horton JC, Cottler LB, et al. A multistate trial of pharmacy syringe purchase. J Urban Health. 2004;81:661–670.PubMedGoogle Scholar
  8. 8.
    Stopka TJ, Singer M, Teng W, et al. Pharmacy access to over-the-counter syringes in Connecticut: implications for HIV and hepatitis prevention among injection drug users. AIDS Public Policy J. 2002;17:115–126.Google Scholar
  9. 9.
    Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc. 2002;42(Suppl 2):S77–S82.Google Scholar
  10. 10.
    Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State expanded syringe access demonstration program. J Acquir Immune Defic Syndr. 2005;39:471–477.PubMedCrossRefGoogle Scholar
  11. 11.
    Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777–813.PubMedCrossRefGoogle Scholar
  12. 12.
    Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001;91:791–793.PubMedCrossRefGoogle Scholar
  13. 13.
    Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. Am J Public Health. 1996;86:642–654.PubMedGoogle Scholar
  14. 14.
    Jones TS, Coffin PO. Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. J Am Pharm Assoc. 2002;42(Suppl 2):S6–S9.Google Scholar
  15. 15.
    Reich W, Compton WM, Horton JC, et al. Injection drug users report good access to pharmacy sale of syringes. J Am Pharm Assoc. 2002;42(Suppl 2):S68–S72.Google Scholar
  16. 16.
    Junge B, Vlahov D, Riley E, Huettner S, Brown M, Beilenson P. Pharmacy access to sterile syringe for injection drug users: attitudes of participants in a syringe exchange program. J Am Pharm Assoc (Wash.). 1999;39:17–22.Google Scholar
  17. 17.
    Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies’ needle and syringe sales—Connecticut, 1992–1993. J Acquir Immune Defic Syndr. 1995;10:73–81.Google Scholar
  18. 18.
    Wright-De Aguero L, Weinstein B, Jones TS, Miles J. Impact of change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers’ practices. J Acquir Immune Defic Syndr. 1998;18(Suppl 1):102–110.Google Scholar
  19. 19.
    Groseclose SL, Weinstein B, Jones T, et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers—Connecticut, 1992–1993. J Acquir Immune Defic Syndr. 1995;10:82–89.Google Scholar
  20. 20.
    Singer M, Himmelgreen D, Weeks MR, Radda KE, Martinez R. Changing the environment of AIDS risk: findings on syringe and pharmacy sales of syringes in Hartford, Connecticut. Med Anthropol. 1997;18:107–130.PubMedCrossRefGoogle Scholar
  21. 21.
    Riley ED, Safaeian M, Strathdee SA, et al. Comparing new participants of a mobile versus a pharmacy-based needle exchange program. J Acquir Immune Defic Syndr. 2000;24:57–61.PubMedGoogle Scholar
  22. 22.
    Farley TA, Niccolai LM, Billeter M, Kissinger PJ, Grace M. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. J Am Pharm Assoc. 1999;39:23–26.Google Scholar
  23. 23.
    Gleghorn AA, Gee G, Vlahov D. Pharmacists’ attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr. 1998;18(Suppl 1):89–93.Google Scholar
  24. 24.
    Reich W, Compton WM, Horton JC, et al. Pharmacist ambivalence about over-the-counter sale of syringes to injection drug users. J Am Pharm Assoc. 2002;42(Suppl 2):S52–S57.Google Scholar
  25. 25.
    Singer M, Stopka T. Diminishing access to over-the-counter (OTC) syringes among injection drug users in Hartford, CT: A longitudinal assessment. Paper presented at 3rd Annual CIRA Science Day. September 21, 2000. Yale University, Dept. of Epidemiology and Public Health. New Haven, Connecticut.Google Scholar
  26. 26.
    Legislative Counsel. State of California. Official California Legislative Information. Accessed on August 16, 2006. Available at: http://www.leginfo.ca.gov.
  27. 27.
    SPSS Inc. SPSS Base 13.0 for Windows User’s Guide. Chicago, Illinois: SPSS Inc.; 2004.Google Scholar

Copyright information

© The New York Academy of Medicine 2006

Authors and Affiliations

  • Thomas J. Stopka
    • 1
  • Richard S. Garfein
  • Alessandra Ross
  • Steven R. Truax
  1. 1.Office of AIDSCalifornia Department of Health ServicesSacramentoUSA

Personalised recommendations